Patents Assigned to Jennerex, Inc.
  • Publication number: 20150037355
    Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
    Type: Application
    Filed: January 4, 2012
    Publication date: February 5, 2015
    Applicants: SILLAJEN, INC., JENNEREX INC.
    Inventors: David Kirn, John Bell, Caroline Breitback, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim
  • Publication number: 20140322173
    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.
    Type: Application
    Filed: May 8, 2014
    Publication date: October 30, 2014
    Applicant: JENNEREX, INC.
    Inventors: DAVID KIRN, CAROLINE BREITBACH
  • Publication number: 20140162342
    Abstract: Certain embodiments are directed to viral production processes for the large scale production of vaccinia virus.
    Type: Application
    Filed: August 3, 2012
    Publication date: June 12, 2014
    Applicant: JENNEREX, INC.
    Inventors: David Kirn, John Bell
  • Patent number: 8747837
    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: June 10, 2014
    Assignee: Jennerex, Inc.
    Inventors: David Kirn, Caroline Breitbach
  • Publication number: 20130183271
    Abstract: The present invention concerns methods and compositions for the treatment of cancer and cancer cells using altered poxviruses, including a vaccinia virus that has been altered to generate a more effective therapeutic agent. Such poxviruses are engineered to be attenuated or weakened in their ability to affect normal cells. In some embodiments, methods and compositions involve poxviruses that possess mutations that result in poxviruses with diminished or eliminated capability to implement an antiviral response in a host. Poxviruses with these mutations in combination with other mutations can be employed for more effective treatment of cancer.
    Type: Application
    Filed: November 13, 2012
    Publication date: July 18, 2013
    Applicant: JENNEREX, INC.
    Inventor: JENNEREX, INC.
  • Patent number: 8329164
    Abstract: The present invention concerns methods and compositions for the treatment of cancer and cancer cells using altered poxviruses, including a vaccinia virus that has been altered to generate a more effective therapeutic agent. Such poxviruses are engineered to be attenuated or weakened in their ability to affect normal cells. In some embodiments, methods and compositions involve poxviruses that possess mutations that result in poxviruses with diminished or eliminated capability to implement an antiviral response in a host. Poxviruses with these mutations in combination with other mutations can be employed for more effective treatment of cancer.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: December 11, 2012
    Assignee: Jennerex, Inc.
    Inventors: David Kirn, Steve H. Thorne
  • Publication number: 20120230958
    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.
    Type: Application
    Filed: September 14, 2010
    Publication date: September 13, 2012
    Applicant: JENNEREX, INC.
    Inventors: David Kirn, Caroline Breitbach